Kimberley M. Heinhuis

Author

Also Known As

Heinhuis, Kimberley M., Heinhuis, Kimberley Marga, K.M. Heinhuis, Kimberley Heinhuis, Kimberley M Heinhuis, Kimberley M. Heinhuis

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Princess Margaret Cancer Centre Utrecht University Oncode Institute European Institute of Oncology

About

Kimberley M. Heinhuis is an author at The Netherlands Cancer Institute specializing in radiation oncology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	174
2	Cell Biology	2	2	33
3	Immunology	1	1	17
4	Molecular Biology	1	1	130
5	Pathology	1	1	16

Kimberley M. Heinhuis

Publications

592

Citations

H-Index

Page 1

	Year	Citations
METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours L.L. Siu, Drew Rasco, S. P. Vinay, Annals of Oncology Molecular BiologyAdvanced Solid TumoursAnti-cancer AgentTumor SuppressorCancer Genetics	2019	130
Detection and localization of early- and late-stage cancers using platelet RNA Sjors G. J. G. In ‘t Veld, Mohammad Arkani, Edward P. Post, Cancer Cell	2022	108
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors Martin Gutierrez, Víctor Moreno, Kimberley M. Heinhuis, Clinical Cancer Research	2020	105
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors Kimberley M. Heinhuis, Matteo S. Carlino, Markus Joerger, JAMA Oncology	2019	90
RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics Kimberley M. Heinhuis, Sjors G. J. G. In ‘t Veld, Govert Dwarshuis, Cancers	2020	54
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, EUR Research Repository (Erasmus University Rotterdam)	2022	50
Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors Jeffrey Clarke, Siu-Chung Chu, Lillian L. Siu, Molecular Cancer Therapeutics ImmunoeditingImmunologyImmunotherapeuticsImmunotherapyTumor Mesothelin Expression	2019	17
Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma Drew Rasco, Anthony W. Tolcher, Lillian L. Siu, Cancer Research Accelerated Dose TitrationPathologyCancer BiologyTumor BiologyDose-escalation Study	2017	16
RNA-Sequencing of Tumor-Educated Platelets, A Novel Biomarker for Blood Based Sarcoma Diagnostics. Kimberley M. Heinhuis, Sjors G. J. G. In ‘t Veld, Govert Dwarshuis, European Journal of Surgical Oncology	2020	11
A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute Kimberley M. Heinhuis, Hannerieke J. Barkman, Jos H. Beijnen, International Journal of Clinical Pharmacy Cost Analysis StudyMedicineVaccine TrialAntibody ScreeningMonoclonal Antibodies	2020	11

Page 1